240 related articles for article (PubMed ID: 20371747)
1. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.
Moriyama B; Henning SA; Childs R; Holland SM; Anderson VL; Morris JC; Wilson WH; Drusano GL; Walsh TJ
Ann Pharmacother; 2010 May; 44(5):929-35. PubMed ID: 20371747
[TBL] [Abstract][Full Text] [Related]
2. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria.
Moriyama B; Henning SA; Neuhauser MM; Danner RL; Walsh TJ
Ann Pharmacother; 2009 Jul; 43(7):1324-37. PubMed ID: 19584386
[TBL] [Abstract][Full Text] [Related]
3. The Pharmacodynamics of Prolonged Infusion β-Lactams for the Treatment of Pseudomonas aeruginosa Infections: A Systematic Review.
Thabit AK; Hobbs ALV; Guzman OE; Shea KM
Clin Ther; 2019 Nov; 41(11):2397-2415.e8. PubMed ID: 31679822
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
Chen M; Buurma V; Shah M; Fahim G
Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Therapeutic Drug Monitoring of Continuous Beta-Lactam Infusion for Osteoarticular Infections Caused by Fluoroquinolone-Resistant Pseudomonas aeruginosa: A Prospective Cohort Study.
Gómez-Junyent J; Rigo-Bonnin R; Benavent E; Soldevila L; Padullés A; Cabo X; Tubau F; Ariza J; Murillo O
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):587-599. PubMed ID: 32440843
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
[TBL] [Abstract][Full Text] [Related]
7. Treatment of multidrug-resistant pseudomonas aeruginosa using extended-infusion antimicrobial regimens.
Heil EL; Lowery AV; Thom KA; Nicolau DP
Pharmacotherapy; 2015 Jan; 35(1):54-8. PubMed ID: 25556715
[TBL] [Abstract][Full Text] [Related]
8. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
[TBL] [Abstract][Full Text] [Related]
9. Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.
Clark ST; Sinha U; Zhang Y; Wang PW; Donaldson SL; Coburn B; Waters VJ; Yau YCW; Tullis DE; Guttman DS; Hwang DM
Int J Antimicrob Agents; 2019 May; 53(5):620-628. PubMed ID: 30664925
[TBL] [Abstract][Full Text] [Related]
10. Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to β-lactams in ICU patients: A pilot study.
Dupont H; Marciniak S; Zogheib E; Mammeri H; Friggeri A; Ammenouche N; Levrard M; Airapetian N; Tinturier F; Mahjoub Y
Anaesth Crit Care Pain Med; 2015 Jun; 34(3):141-4. PubMed ID: 26004874
[TBL] [Abstract][Full Text] [Related]
11. Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients.
Thompson RZ; Martin CA; Burgess DR; Rutter WC; Burgess DS
J Cyst Fibros; 2016 Sep; 15(5):660-3. PubMed ID: 27132188
[TBL] [Abstract][Full Text] [Related]
12. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
13. In vivo impact of the MexAB-OprM efflux system on beta-lactam efficacy in an experimental model of Pseudomonas aeruginosa infection.
Boutoille D; Jacqueline C; Le Mabecque V; Potel G; Caillon J
Int J Antimicrob Agents; 2009 May; 33(5):417-20. PubMed ID: 19157801
[TBL] [Abstract][Full Text] [Related]
14. Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa.
Ferrari F; Lu Q; Girardi C; Petitjean O; Marquette CH; Wallet F; Rouby JJ;
Intensive Care Med; 2009 Oct; 35(10):1792-800. PubMed ID: 19652947
[TBL] [Abstract][Full Text] [Related]
15. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME
Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates.
Idowu T; Ammeter D; Arthur G; Zhanel GG; Schweizer F
J Antimicrob Chemother; 2019 Sep; 74(9):2640-2648. PubMed ID: 31139830
[TBL] [Abstract][Full Text] [Related]
17. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa.
Pilmis B; Petitjean G; Lesprit P; Lafaurie M; El Helali N; Le Monnier A;
Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1457-1461. PubMed ID: 31073653
[TBL] [Abstract][Full Text] [Related]
18. Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.
Papp-Wallace KM; Zeiser ET; Becka SA; Park S; Wilson BM; Winkler ML; D'Souza R; Singh I; Sutton G; Fouts DE; Chen L; Kreiswirth BN; Ellis-Grosse EJ; Drusano GL; Perlin DS; Bonomo RA
J Infect Dis; 2019 Jul; 220(4):666-676. PubMed ID: 31099835
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
Santevecchi BA; Smith TT; MacVane SH
Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
[TBL] [Abstract][Full Text] [Related]
20. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
